Dr. Chagpar on Novel Agents for Neoadjuvant TNBC Treatment

Anees B. Chagpar, MD
Published: Friday, Mar 10, 2017


Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.

TNBC represents about one-fifth of all breast cancers, Chagpar explains. Historically, it has been associated with a poor prognosis.

As patients with TNBC respond well to neoadjuvant chemotherapy, there has been a number of clinical trials looking at novel agents in this subset of patients. For example, platinum-based agents seem to work well in TNBC, she says.

Patients with TNBC tend to have a high rate of tumor infiltrating lymphocytes, Chagpar explains, so this is a potentially exciting target for immunotherapy. Clinical trials have shown immunotherapy works well in heavily pre-treated patients with metastatic breast cancer, and Chagpar believes an ongoing trial looking at neoadjuvant immunotherapy in early-stage TNBC has the potential to change disease management for these patients.

<<< View more from the 2017 Miami Breast Cancer Conference

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.

TNBC represents about one-fifth of all breast cancers, Chagpar explains. Historically, it has been associated with a poor prognosis.

As patients with TNBC respond well to neoadjuvant chemotherapy, there has been a number of clinical trials looking at novel agents in this subset of patients. For example, platinum-based agents seem to work well in TNBC, she says.

Patients with TNBC tend to have a high rate of tumor infiltrating lymphocytes, Chagpar explains, so this is a potentially exciting target for immunotherapy. Clinical trials have shown immunotherapy works well in heavily pre-treated patients with metastatic breast cancer, and Chagpar believes an ongoing trial looking at neoadjuvant immunotherapy in early-stage TNBC has the potential to change disease management for these patients.

<<< View more from the 2017 Miami Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x